Diana Bhatt

Diana Bhatt specializes in the management of premenopausal women with hormone receptor-positive breast cancer, examining optimal endocrine strategies combining ovarian function suppression with aromatase inhibitors or tamoxifen. Her research has contributed to translating SOFT and TEXT trial findings into clinical practice, identifying which premenopausal women benefit from ovarian suppression plus aromatase inhibitor versus tamoxifen alone based on clinical and genomic risk factors. She has studied fertility preservation strategies for premenopausal women with HR+ breast cancer who wish to conceive after completing treatment, and the oncologic safety of temporary treatment interruption for fertility in low-risk cases. Her clinical research addresses the unique challenges of managing early breast cancer in young women while balancing treatment intensity, toxicity, and quality of life.